CRISPR THERAPEUTICS AG
Income Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $517.0K | $504.0K | $201.2M | $0 | $70.0M | $100.0M | $6.0K | $94.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $80.2M | $76.2M | $95.1M | $90.7M | $101.6M | $99.9M | $103.6M | $116.6M |
| SG&A Expense | $19.5M | $18.0M | $16.5M | $18.3M | $19.0M | $22.4M | $21.2M | $27.0M |
| Operating Income | $-151.3M | $-140.6M | $69.6M | $-132.4M | $-95.2M | $-64.5M | $-131.5M | $-182.4M |
| Operating Margin | -29,257.3% | -27,894.2% | 34.6% | — | -136.0% | -64.5% | -2,192,350.0% | -194,029.8% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-125.1M | $-115.9M | $89.6M | $-111.7M | $-76.8M | $-51.7M | $-120.1M | $-175.1M |
| Income Tax Expense | $1.3M | $724.0K | $233.0K | $412.0K | $923.0K | $1.3M | $-9.5M | $-575.0K |
| Net Income | $-126.4M | $-116.6M | $89.3M | $-112.2M | $-77.7M | $-53.1M | $-110.6M | $-174.5M |
| Net Margin | -24,450.3% | -23,133.1% | 44.4% | — | -111.1% | -53.1% | -1,842,916.7% | -185,690.4% |
| EPS (Basic) | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 |
| EPS (Diluted) | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 |
| Shares Outstanding (Basic) | 84.9M | 81.8M | 79.2M | 79.4M | 79.1M | 78.7M | 77.7M | 78.0M |
| Shares Outstanding (Diluted) | 84.9M | 81.8M | 79.2M | 79.4M | 79.1M | 78.7M | 77.7M | 78.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |